MedTrace Logo

Arm Exercise Capacity and Maximal Oxygen Consumption With Breast Cancer

NCT06018038 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-05-19

No results posted yet for this study

Summary

Breast cancer is the most common type of cancer among women worldwide. The incidence rate has reached approximately 16%. According to 2016 data from the Ministry of Health, the incidence of breast cancer in Turkey is 46.8 per 100,000 people and approximately 17,000 women are diagnosed with breast cancer each year. While breast cancer survival rate is 80% in developed countries, this rate varies between 40-60% in low-middle income countries. Survival can be increased with early diagnosis and more effective treatment methods. However, a wide range of treatment-related complications are observed during and/or after breast cancer treatment. Cancer survivors are exposed to a variety of direct (local/regional therapy, systemic therapy and supportive care) and indirect factors (modifiable and non-modifiable risk factors) that can have adverse effects on pulmonary, cardiovascular, hematologic and musculoskeletal components. Oxygen consumption in cancer patients may be adversely affected by aging, deconditioning, existing comorbidities, cancer pathophysiology and cancer treatments (surgery, radiation, chemotherapy and hormone therapy). Although decreased functional capacity is common after breast cancer treatment, there are few studies evaluating maximal arm exercise capacity with oxygen consumption.

Conditions

Interventions

DIAGNOSTIC_TEST

Arm Exercise Capacity, Peak Oxygen Consumption (VO2peak)

peak arm exercise capacity

DIAGNOSTIC_TEST

Muscle oxygenation

Muscle oxygenation (SmO2 ) was recorded using a device (Moxy, Fortiori Design LLC, Minnesota, USA) that measures local SmO2 in muscle capillaries using near-infrared spectroscopy (NIRS)

Sponsors & Collaborators

  • Hacettepe University

    lead OTHER

Principal Investigators

  • Ebru Calik Kutukcu, PhD · Hacettepe University

  • Melda Saglam, PhD · Hacettepe University

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-09-01
Completion
2024-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06018038 on ClinicalTrials.gov